153 related articles for article (PubMed ID: 30249354)
1. Discovery of potent and selective Spleen Tyrosine Kinase inhibitors for the topical treatment of inflammatory skin disease.
Barker MD; Liddle J; Atkinson FL; Wilson DM; Dickson MC; Ramirez-Molina C; Lewis H; Davis RP; Somers DO; Neu M; Jones E; Watson R
Bioorg Med Chem Lett; 2018 Nov; 28(21):3458-3462. PubMed ID: 30249354
[TBL] [Abstract][Full Text] [Related]
2. 3-aminopyrazolopyrazine derivatives as spleen tyrosine kinase inhibitors.
Shen J; Li X; Zhang Z; Luo J; Long H; Tu Z; Zhou X; Ding K; Lu X
Chem Biol Drug Des; 2016 Nov; 88(5):690-698. PubMed ID: 27264434
[TBL] [Abstract][Full Text] [Related]
3. GSK2646264, a spleen tyrosine kinase inhibitor, attenuates the release of histamine in ex vivo human skin.
Ramirez Molina C; Falkencrone S; Skov PS; Hooper-Greenhill E; Barker M; Dickson MC
Br J Pharmacol; 2019 Apr; 176(8):1135-1142. PubMed ID: 30735243
[TBL] [Abstract][Full Text] [Related]
4. Crystal structures of spleen tyrosine kinase in complex with novel inhibitors: structural insights for design of anticancer drugs.
Lee SJ; Choi JS; Han BG; Kim HS; Song HJ; Lee J; Nam S; Goh SH; Kim JH; Koh JS; Lee BI
FEBS J; 2016 Oct; 283(19):3613-3625. PubMed ID: 27504936
[TBL] [Abstract][Full Text] [Related]
5. Discovery of TAK-659 an orally available investigational inhibitor of Spleen Tyrosine Kinase (SYK).
Lam B; Arikawa Y; Cramlett J; Dong Q; de Jong R; Feher V; Grimshaw CE; Farrell PJ; Hoffman ID; Jennings A; Jones B; Matuszkiewicz J; Miura J; Miyake H; Natala SR; Shi L; Takahashi M; Taylor E; Wyrick C; Yano J; Zalevsky J; Nie Z
Bioorg Med Chem Lett; 2016 Dec; 26(24):5947-5950. PubMed ID: 27839918
[TBL] [Abstract][Full Text] [Related]
6. Discovery of new Syk inhibitors through structure-based virtual screening.
Huang Y; Zhang Y; Fan K; Dong G; Li B; Zhang W; Li J; Sheng C
Bioorg Med Chem Lett; 2017 Apr; 27(8):1776-1779. PubMed ID: 28268139
[TBL] [Abstract][Full Text] [Related]
7. Discovery of GSK143, a highly potent, selective and orally efficacious spleen tyrosine kinase inhibitor.
Liddle J; Atkinson FL; Barker MD; Carter PS; Curtis NR; Davis RP; Douault C; Dickson MC; Elwes D; Garton NS; Gray M; Hayhow TG; Hobbs CI; Jones E; Leach S; Leavens K; Lewis HD; McCleary S; Neu M; Patel VK; Preston AG; Ramirez-Molina C; Shipley TJ; Skone PA; Smithers N; Somers DO; Walker AL; Watson RJ; Weingarten GG
Bioorg Med Chem Lett; 2011 Oct; 21(20):6188-94. PubMed ID: 21903390
[TBL] [Abstract][Full Text] [Related]
8. Safety, pharmacokinetics and pharmacodynamics of a topical SYK inhibitor in cutaneous lupus erythematosus: A double-blind Phase Ib study.
Walker A; Erwig L; Foster K; Nevin K; Wenzel J; Worm M; Williams N; Ratia N; Hoang B; Schneider-Merck T; Gisbert S; Carnarius H; Dickson M
Exp Dermatol; 2021 Nov; 30(11):1686-1692. PubMed ID: 33336508
[TBL] [Abstract][Full Text] [Related]
9. Optimization of a series of potent, selective and orally bioavailable SYK inhibitors.
Grimster NP; Gingipalli L; Barlaam B; Su Q; Zheng X; Watson D; Wang H; Simpson I; Pike A; Balazs A; Boiko S; Ikeda TP; Impastato AC; Jones NH; Kawatkar S; Kemmitt P; Lamont S; Patel J; Read J; Sarkar U; Sha L; Tomlinson RC; Wang H; Wilson DM; Zehnder TE; Wang L; Wang P; Goldberg FW; Shao W; Fawell S; Dry H; Dowling JE; Edmondson SD
Bioorg Med Chem Lett; 2020 Oct; 30(19):127433. PubMed ID: 32717371
[TBL] [Abstract][Full Text] [Related]
10. Novel potent and selective pyrazolylpyrimidine-based SYK inhibitors.
Barlaam B; Boiko S; Boyd S; Dry H; Gingipalli L; Ikeda T; Johnson T; Kawatkar S; Lorthioir O; Pike A; Pollard H; Read J; Su Q; Wang H; Wang H; Wang L; Wang P; Edmondson SD
Bioorg Med Chem Lett; 2020 Nov; 30(22):127523. PubMed ID: 32877741
[TBL] [Abstract][Full Text] [Related]
11. Synthesis and optimization of furano[3,2-d]pyrimidines as selective spleen tyrosine kinase (Syk) inhibitors.
Hoemann M; Wilson N; Argiriadi M; Banach D; Burchat A; Calderwood D; Clapham B; Cox P; Duignan DB; Konopacki D; Somal G; Vasudevan A
Bioorg Med Chem Lett; 2016 Nov; 26(22):5562-5567. PubMed ID: 27789138
[TBL] [Abstract][Full Text] [Related]
12. Ligand-based and e-pharmacophore modeling, 3D-QSAR and hierarchical virtual screening to identify dual inhibitors of spleen tyrosine kinase (Syk) and janus kinase 3 (JAK3).
Kaur M; Silakari O
J Biomol Struct Dyn; 2017 Nov; 35(14):3043-3060. PubMed ID: 27678281
[TBL] [Abstract][Full Text] [Related]
13. Discovery of a novel series of pyridine and pyrimidine carboxamides as potent and selective covalent inhibitors of Btk.
Caldwell R; Liu-Bujalski L; Qiu H; Mochalkin I; Jones R; Neagu C; Goutopoulos A; Grenningloh R; Johnson T; Sherer B; Gardberg A; Follis AV; Morandi F; Head J
Bioorg Med Chem Lett; 2018 Nov; 28(21):3419-3424. PubMed ID: 30290988
[TBL] [Abstract][Full Text] [Related]
14. Discovery of a Natural Syk Inhibitor from Chinese Medicine through a Docking-Based Virtual Screening and Biological Assay Study.
Wang X; Guo J; Ning Z; Wu X
Molecules; 2018 Nov; 23(12):. PubMed ID: 30487406
[TBL] [Abstract][Full Text] [Related]
15. Identification of a novel series of azabenzimidazole-derived inhibitors of spleen tyrosine kinase.
Kawatkar SP; Barlaam B; Kemmitt P; Simpson I; Watson D; Wang P; Lamont S; Su Q; Boiko S; Ikeda T; Patel J; Pike A; Pollard H; Read J; Sarkar U; Wang H; Wen Q; Yan Z; Dowling JE; Dry H; Edmondson SD
Bioorg Med Chem Lett; 2020 Sep; 30(18):127393. PubMed ID: 32721854
[TBL] [Abstract][Full Text] [Related]
16. Discovery and SAR of novel 4-thiazolyl-2-phenylaminopyrimidines as potent inhibitors of spleen tyrosine kinase (SYK).
Farmer LJ; Bemis G; Britt SD; Cochran J; Connors M; Harrington EM; Hoock T; Markland W; Nanthakumar S; Taslimi P; Ter Haar E; Wang J; Zhaveri D; Salituro FG
Bioorg Med Chem Lett; 2008 Dec; 18(23):6231-5. PubMed ID: 18938080
[TBL] [Abstract][Full Text] [Related]
17. Design and optimization of orally spleen tyrosine kinase (SYK) inhibitors for treatment of solid tumor.
Wang C; Wang X; Li Y; Wang T; Huang Z; Qin Z; Yang S; Xiang R; Fan Y
Bioorg Chem; 2020 Jan; 95():103547. PubMed ID: 31911307
[TBL] [Abstract][Full Text] [Related]
18. Discovery of novel imidazo[1,2-a]pyridines as inhibitors of the insulin-like growth factor-1 receptor tyrosine kinase.
Ducray R; Simpson I; Jung FH; Nissink JW; Kenny PW; Fitzek M; Walker GE; Ward LT; Hudson K
Bioorg Med Chem Lett; 2011 Aug; 21(16):4698-701. PubMed ID: 21775140
[TBL] [Abstract][Full Text] [Related]
19. Design, Synthesis, and Structure-Activity Relationships of Pyridine-Based Rho Kinase (ROCK) Inhibitors.
Green J; Cao J; Bandarage UK; Gao H; Court J; Marhefka C; Jacobs M; Taslimi P; Newsome D; Nakayama T; Shah S; Rodems S
J Med Chem; 2015 Jun; 58(12):5028-37. PubMed ID: 26039570
[TBL] [Abstract][Full Text] [Related]
20. 4-Amino-2-arylamino-6-(2,6-dichlorophenyl)-pyrido[2,3-d]pyrimidin-7-(8H)-ones as BCR kinase inhibitors for B lymphoid malignancies.
Puig de la Bellacasa R; Roué G; Balsas P; Pérez-Galán P; Teixidó J; Colomer D; Borrell JI
Eur J Med Chem; 2014 Oct; 86():664-75. PubMed ID: 25222877
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
